Our focus is on the molecules and/or pathways in protein translation that are disturbed by energy deficiency and aberrant AMPK activation in neurodegenerative diseases, with a specific focus on Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). This evidence concerns the gene PRKAA2 and Alzheimer disease.